Immuron expands PROIBS into U.S. market
- Immuron (NASDAQ:IMRN) signed an exclusive U.S. distribution agreement with Calmino group AB for digestive health product PROIBS®.
- The agreement targets the U.S. digestive and gut health supplement market, valued at $4.16 billion.
- A Calmino usability study found 94% of 1,003 users reported PROIBS® was helpful.
Immuron (NASDAQ:IMRN) announced an exclusive U.S. distribution agreement with Calmino group AB for PROIBS®, a digestive health product designed to support abdominal comfort and intestinal health.
The agreement expands PROIBS® availability beyond Australia, where Immuron launched the product in fiscal 2026, and introduces the product to the U.S. digestive and gut health supplement market.
PROIBS® contains AVH200® from Aloe barbadensis Mill and is a European-certified medical device designed for symptoms including abdominal pain, bloating, and unsettled bowel movements.
Calmino reported that its usability study involving 1,003 users found 94% of participants considered PROIBS® helpful, 91% reported improved daily life, and 98% said they would recommend the product.
Following the announcement the Immuron share price was not provided in the announcement.
Immuron and Calmino will focus on distribution and commercialization activities for PROIBS® in the United States, where the digestive health supplement segment is valued at approximately $4.16 billion.
Immuron develops and commercializes health products based on oral immunotherapies and related technologies, with activities spanning digestive health and other therapeutic areas.
